Hikma Pharmaceuticals (HIK) Stock Rating Reaffirmed by Barclays
Barclays restated their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research report report published on Friday. The brokerage currently has a GBX 1,950 ($25.48) price objective on the stock.
HIK has been the topic of several other research reports. Peel Hunt restated an add rating on shares of Hikma Pharmaceuticals in a report on Tuesday, September 4th. Numis Securities restated a hold rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 15th. JPMorgan Chase & Co. restated a neutral rating and set a GBX 1,050 ($13.72) price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, August 21st. Finally, Citigroup upped their price objective on shares of Hikma Pharmaceuticals from GBX 1,675 ($21.89) to GBX 2,100 ($27.44) and gave the stock a buy rating in a report on Monday, August 20th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of GBX 1,459 ($19.06).
HIK traded down GBX 170.50 ($2.23) during trading on Friday, hitting GBX 1,854.50 ($24.23). 1,517,297 shares of the company’s stock were exchanged, compared to its average volume of 822,138. Hikma Pharmaceuticals has a fifty-two week low of GBX 814.20 ($10.64) and a fifty-two week high of GBX 2,346 ($30.65).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Recommended Story: Consumer behavior in bull markets
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.